Literature DB >> 8912950

Lithium-responsive affective disorders: no association with the tyrosine hydroxylase gene.

P Cavazzoni1, M Alda, G Turecki, G Rouleau, E Grof, R Martin, A Duffy, P Grof.   

Abstract

Family, adoption, and twin studies have demonstrated the involvement of genetic factors in the etiology of major affective disorders. In an attempt to identify the involved genes, several linkage and association studies have focused on the gene coding for tyrosine hydroxylase, the rate-limiting enzyme in catecholamine synthesis. The discrepant results to date could be explained by etiological heterogeneity, which may be substantially reduced by selecting patients according to lithium response. Therefore, we investigated 54 patients who had shown definite long-term response to lithium monotherapy in spite of a high risk of recurrence as indicated by the previous clinical course. All the subjects suffered from major affective disorder by Research Diagnostic Criteria (48 bipolar, 6 recurrent unipolar). They were compared to 94 population controls of similar ethnic background to test for association with a penta-allelic microsatellite marker found within the tyrosine hydroxylase gene. No significant differences in allele and genotype frequencies were observed between the two groups, providing further evidence against a major role for the tyrosine hydroxylase gene in the etiology of major affective disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912950     DOI: 10.1016/0165-1781(96)02888-0

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

Review 4.  Pharmacogenetics of lithium response in bipolar disorder.

Authors:  M Alda
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

Review 5.  Response to treatment in bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Guy Rouleau; Gustavo Turecki
Journal:  Curr Opin Psychiatry       Date:  2011-01       Impact factor: 4.741

6.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 7.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

Review 8.  Post-genomic era and gene discovery for psychiatric diseases: there is a new art of the trade? The example of the HUMTH01 microsatellite in the Tyrosine Hydroxylase gene.

Authors:  Rolando Meloni; Nicole Faucon Biguet; Jacques Mallet
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

9.  Molecular linkage studies of bipolar disorder.

Authors:  W H Berrettini
Journal:  Dialogues Clin Neurosci       Date:  1999-06       Impact factor: 5.986

Review 10.  Sex-specific effects of LiCl treatment on preservation of renal function and extended life-span in murine models of SLE: perspective on insights into the potential basis for survivorship in NZB/W female mice.

Authors:  David A Hart
Journal:  Biol Sex Differ       Date:  2016-06-27       Impact factor: 5.027

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.